Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00260234 |
|
Recruitment Status :
Terminated
(Stopped in December 2007)
First Posted : December 1, 2005
Last Update Posted : September 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 1 | Biological: Allogeneic Cultured Islet Cells (human); Encapsulated | Phase 1 Phase 2 |
Allogeneic Cultured Islet Cells (human, Novocell); Encapsulated in Polyethylene Glycol; Administered Subcutaneously are a combination biologic and device product in which the pharmacologically active agent is human insulin that is released from the functional islet cells by natural production and release, stimulated by control mechanisms in response to blood glucose concentrations. The device component is a uniform and conformal polymer coating around each islet. Islet cells are isolated from multiple human pancreases procured from human organ donors who meet a specific human donor profile established by the UNOS and the FDA's requirements for Good Tissue Practices. Because the pancreases used for islet cell isolation are not intended for whole-organ transplantation, specific procurement, surgical removal, packaging and shipping protocols are provided by Novocell, Inc. to the Organ Procurement Organizations.
The primary outcome is demonstration that encapsulated islet allografts can be implanted safely in the subcutaneous tissues without the use of long-term immunosuppression. The expected functional outcomes from the implantation of the encapsulated islets are significant reductions in the average blood glucose daily glycemic excursions and in insulin requirements as well as significant increases in C-peptide levels in response to meal challenges. The ultimate expected outcome is that patients who receive these implants will have reduced hemoglobin A1c levels that may be associated with reduced long-term diabetic complications. An important outcome should be reduction in hypoglycemic episodes and crises with significantly functioning grafts without having the risks associated with hepatic portal vein infusion and long-term immunosuppression.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 12 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes |
| Study Start Date : | November 2005 |
| Actual Primary Completion Date : | December 2007 |
| Actual Study Completion Date : | December 2007 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: PEG Islet Cells |
Biological: Allogeneic Cultured Islet Cells (human); Encapsulated |
- Safety - will be evaluated by the incidence, grade, and type of adverse events, changes in laboratory parameters, evaluation of the implant site and physical exams.
- Efficacy - will be assessed by:
- Blood glucose levels
- Daily glycemic excursions
- Pre-prandial glucose levels
- Post-prandial glucose levels
- Glucose responses from OGTT (mg/dL and AUC:glucose
- Stimulated C-peptide levels from OGTT (ng/mL and
- AUC:C-Peptide
- HbA1c (%)
- Insulin requirements (units/day)
- Arginine stimulation tests
- Numbers of hypoglycemic and hyperglycemic episodes
- Functional duration - will be determined by stimulated C-peptide from OGTT.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or non-pregnant non-lactating female subjects > 20 years of age
- Diagnosed with insulin-dependent type I diabetes for at least 20 years
- BMI less than 28 kg/m2
- Insulin requirement less than or equal to 0.7 U/kg/day
- HbA1c greater than or equal to 7.0 %
- Serum C-peptide concentration less than or equal to 0.5 ng/mL stimulated by an OGTT
- Female subjects with childbearing potential must have a negative serum pregnancy test prior to enrollment and must agree to use an effective contraceptive method during the study
- One year of stable diabetes care established in the PI's database without significant changes in insulin requirement or HbA1c or diabetic complication profile
Exclusion Criteria:
- Diagnosis of type II diabetes or maturity onset diabetes of youth (MODY)
- Serum C-peptide greater than 0.5 ng/mL stimulated by OGTT
- Sustained hypertension greater than or equal to 100 mmHg diastolic and/or greater than or equal to 160 mmHg systolic
- History of myocardial infarction or current active cardiac disease
- Current active infection
- Significant renal dysfunction as indicated by GFR less than 80 mL/min/1.73 m2 and/or urinary albumin greater than 500 µg/mL
- Significant liver dysfunction as indicated by ALT or AST more than 3X the upper limit of normal
- Prior whole organ or islet cell transplant
- Concurrent immunosuppressive therapy
- Severe gastroparesis, severe peripheral neuropathy, diabetic foot ulcers, or prior amputations due to diabetic complications
- Any other active autoimmune disease other than autoimmune thyroid disease
- HIV, HBV or HCV positive status
- Uncontrolled or untreated proliferative retinopathy
- Known hypersensitivity or other intolerance to cyclosporine or the inactive ingredients in the product
- Behavioral activities that place the subject at risk in the opinion of the investigator
- Any significant concurrent disease, illness, or psychiatric disorder that would, in the opinion of the investigator, compromise subject safety or compliance, or interfere with consent, study participation, follow-up, or the interpretation of study results
- History of any kind of cancer other than skin cancers (except for melanoma which is exclusionary)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00260234
| United States, Texas | |
| CHRISTUS Santa Rosa Transplant Institute | |
| San Antonio, Texas, United States, 78229 | |
| Diabetes & Glandular Disease Research Associates, P.A. | |
| San Antonio, Texas, United States, 78229 | |
| Principal Investigator: | Sherwyn Schwartz, M.D. | Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX | |
| Principal Investigator: | Paraic Mulgrew, M.D. | CHRISTUS Santa Rosa Transplant Institute, San Antonio, TX |
Additional Information:
Diabetes & Glandular Disease Research Associates website
CHRISTUS Santa Rosa website
| Responsible Party: | Novocell |
| ClinicalTrials.gov Identifier: | NCT00260234 History of Changes |
| Other Study ID Numbers: |
NC-PCIA-04-001 WIRB #20041068 |
| First Posted: | December 1, 2005 Key Record Dates |
| Last Update Posted: | September 9, 2014 |
| Last Verified: | September 2014 |
|
Transplantation, Pancreatic Islets Diabetes Mellitus, Type 1 Insulin Dependent Islet Transplant |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |